^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

    i
    Other names: ROS1, ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, V-Ros Avian UR2 Sarcoma Virus Oncogene Homolog 1, C-Ros Oncogene 1 Receptor Tyrosine Kinase, Proto-Oncogene Tyrosine-Protein Kinase ROS, Proto-Oncogene C-Ros-1, MCF3, ROS, V-Ros UR2 Sarcoma Virus Oncogene Homolog 1 (Avian), ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, Transmembrane Tyrosine-Specific Protein Kinase, Receptor Tyrosine Kinase C-Ros Oncogene 1, C-Ros Receptor Tyrosine Kinase, Proto-oncogene C-Ros, C-Ros-1
    1d
    Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Fred Hutchinson Cancer Center
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • MSI-H/dMMR • ALK rearrangement
    |
    Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)
    2d
    Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis. (PubMed, Oncologist)
    Many repotrectinib AEs, including neurological AEs secondary to TRK inhibition, were mitigated with appropriate management, including dose modification and/or pharmacologic intervention.
    Journal • Adverse events
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    ROS1 fusion • ROS1 positive • NTRK positive • NTRK fusion
    |
    Augtyro (repotrectinib)
    4d
    A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=68, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Dec 2026 --> Jun 2030
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ALK fusion • ROS1 fusion • ROS1 positive
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib)
    4d
    JK06.1.01: A Phase 1/2, Multicenter, Open Label, Dose Escalation and Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unresectable Locally Advanced or Metastatic Cancer (2024-512421-92-00)
    P1/2, N=305, Recruiting, Salubris Biotherapeutics Inc. | N=210 --> 305
    Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    HER-2 positive • EGFR mutation • HR positive • HER-2 negative • ALK mutation • ROS1 fusion • ESR1 mutation • HER-2 negative + HR negative • HER-2 negative + HR positive + ESR1 mutation
    5d
    Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC (clinicaltrials.gov)
    P2, N=1, Terminated, University of Texas Southwestern Medical Center | N=52 --> 1 | Active, not recruiting --> Terminated; Sponsor decision to halt funding.
    Enrollment change • Trial termination
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • BRAF V600 • ALK rearrangement • ROS1 fusion • NTRK fusion
    |
    Imfinzi (durvalumab)
    5d
    BNT326-02: A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=420, Recruiting, BioNTech SE
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • PD-L1 negative • RET mutation • MET mutation • EGFR negative
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pumitamig (BNT327) • BNT326 • MK-3475 SC
    6d
    Prognostic significance of RICTOR mutations in EGFR-mutant metastatic lung adenocarcinoma: a retrospective cohort study. (PubMed, Virchows Arch)
    RICTOR mutations were associated with a high-risk subset of EGFR-mutant metastatic lung adenocarcinoma characterized by more aggressive clinical features and worse survival. These findings suggest the need for prospective validation and support the potential integration of RICTOR status into molecular risk stratification frameworks for precision oncology.
    Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2)
    |
    BRAF V600E • EGFR mutation • KRAS G12C • EGFR exon 19 deletion • EGFR exon 20 insertion • KRAS G12
    |
    TruSight Oncology 500 Assay
    6d
    Serum Carcinoembryonic Antigen Levels Across Molecular Subtypes and Their Clinical and Prognostic Implications in Metastatic Non-Small Cell Lung Cancer. (PubMed, Medicina (Kaunas))
    However, given the variability across subgroups and modest effect sizes, these findings should be interpreted with caution. Prospective studies evaluating longitudinal CEA dynamics are warranted.
    Clinical • Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    KRAS mutation • EGFR mutation
    6d
    Non-Small-Cell Lung Cancer: From Histopathological Classification to Precision Oncology-A Narrative Review. (PubMed, J Clin Med)
    By emphasizing the interplay between tumor biology, diagnostic workflows, and treatment selection, this review underscores the necessity of comprehensive molecular testing and data integration. Finally, we discuss emerging biomarkers and rational combination strategies that promise to further refine patient stratification and improve outcomes.
    Review • Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    9d
    Thoracic inflammatory myofibroblastic tumors: A decade-long retrospective study integrating clinicopathological and molecular features from a tertiary care centre. (PubMed, Virchows Arch)
    Primary thoracic IMT affects children and young adults. Majority are driven by ALK gene rearrangements, followed by ROS1 alterations, underscoring role of molecular profiling in potential therapeutic stratification.
    Retrospective data • Journal
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)
    |
    ALK rearrangement
    10d
    A Phase II Study of GC101 in NSCLC (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Shanghai Juncell Therapeutics
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • MET exon 14 mutation • RET mutation • MET mutation • KRAS G12 • EGFR negative • NTRK fusion
    |
    GC101 TIL
    10d
    ATATcH Alternating Treatment Plans for Advanced Cancer (clinicaltrials.gov)
    P2, N=150, Recruiting, Rutgers, The State University of New Jersey | Trial completion date: Dec 2025 --> May 2028 | Trial primary completion date: May 2025 --> May 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • MET exon 14 mutation • MET mutation • ALK translocation
    |
    Keytruda (pembrolizumab) • carboplatin • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed